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Triterpenoids echinocystic acid and its glycosides, isolated from several Eclipta prostrata, have been re-
ported to possess various biological activities such as anti-inﬂammatory, anti-bacterial, and anti-diabetic
activity. However, the cytotoxicity of the triterpenoids in human cancer cells and their molecular
mechanism of action are poorly understood. In the present study, we found that eclalbasaponin II with
one glucose moiety has potent cytotoxicity in three ovarian cancer cells and two endometrial cancer cells
compared to an aglycone echinocystic acid and eclalbasaponin I with two glucose moiety. Eclalbasaponin
II treatment dose-dependently increased sub G1 population. Annexin V staining revealed that eclalba-
saponin II induced apoptosis in SKOV3 and A2780 ovarian cancer cells. In addition, eclalbasaponin II-
induced cell death was associated with characteristics of autophagy; an increase in acidic vesicular
organelle content and elevation of the levels of LC3-II. Interestingly, autophagy inhibitor BaF1 suppressed
the eclalbasaponin II-induced apoptosis. Moreover, eclalbasaponin II activated JNK and p38 signaling and
inhibited the mTOR signaling. We further demonstrated that pre-treatment with a JNK and p38 inhibitor
and mTOR activator attenuated the eclalbasaponin II-induced autophagy. This suggests that eclalbasa-
ponin II induces apoptotic and autophagic cell death through the regulation of JNK, p38, and mTOR
signaling in human ovarian cancer cells.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ovarian cancer is the ﬁfth leading cause of cancer-related deaths
among women in development countries. Due to the lack of early-
stage symptoms and the associated difﬁculty of early detection,
most patients are diagnosed at an advanced stage. Patients are
treated with cyto-reductive surgery at an advanced stage, followed
by chemotherapy. Although an initial complete clinical response to
paclitaxel-/platinum-based chemotherapy is seen in 70% of pa-
tients, the majority of these patients will experience recurrence of
the disease within 2 years and the 5-year survival rates arey, Kyung Hee University,
Korea. Tel.: þ82 2 961 2172;
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).approximately 20e25% (1,2). Therefore, there is an urgent need for
new therapeutic agents for late-stage and recurrent ovarian cancer.
Type I programmed cell death, apoptosis, is widely investigated
modality of programed cell death. It is characterized by chromatin
condensation, nucleosomal DNA fragmentation, formation of
apoptotic bodies, and activation of caspases. Many conventional
cancer drugs are known to induce tumor cell death via the
apoptosis pathway. Type II programmed cell death, autophagic cell
death, is characterized by the appearance of autophagosomes,
which engulf bulk cytoplasm and cytoplasmic organelles. Auto-
phagy is an evolutionarily conserved catabolic process for the
degradation and recycling of cytosolic, long-lived, or aggregated
proteins, and excess or defective organelles, and is primarily a
response to the stress of irradiation (3), chemotherapeutic agents
(4), and starvation (5). Despite of its dual role in cell survival and
cell death (6,7), a number of studies have demonstrated that
various anti-tumor agents induce cell death with autophagic fea-
tures in several cancer cells (8e10).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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commonly known as False Daisy, is a common herb widely
distributed throughout tropical and subtropical countries in Asia
(11). It has been reported to have anti-malaria, anti-HIV, anti-
venom, antioxidant, anti-inﬂammatory, and anti-cancer activities
(12e17). The phytochemical studies on Eclipta species revealed the
presence of a wide range of bioactive compounds such as coume-
stans, alkaloids, thiophenes, ﬂavonoids, and triterpenes and their
glycosides (18e20). A coumestan wedelolactone isolated from the
plant has been well-demonstrated to have anti-inﬂammatory ac-
tivities by inhibiting IkB kinase (IKK), which plays a critical role in
the activation of inﬂammatory signaling (21). Despite of several
reports on anti-cancer activities of E. prostrate (16,22,23), the
cytotoxicity of compounds isolated from the plant and its under-
lying molecular mechanism of action have been poorly understood.
A recent study reported that, among the four active compounds
(wedelolactone, eclalbasaponin I, luteolin, and luteolin-7-O-
glucoside) isolated from E. prostrate, only eclalbasaponin I exhibited
mild growth inhibitory effects (IC50 ¼ 111.17 ug/ml) on hepatoma
smmc-7721 cells (24).
In the present study, we investigated the cytotoxicity of tri-
terpenoid echinocystic acid and its glycoside eclalbasaponin I and
eclalbasaponin II, which are isolated from E. prostrate, in human
ovarian and endometrial cancer cells. Among the three compounds,
eclalbasaponin II exhibited potent tumoricidal activity against both
ovarian and endometrial cancer cells. Therefore, we investigated
the cytotoxic effect of eclalbasaponin II and its molecular mecha-
nism of action in ovarian cancer cells.
2. Materials and methods
2.1. Materials
Echinocystic acid, eclalbasaponin I, and eclalbasaponin II used in
this study were isolated from Eclipta prostrata L. as reported pre-
viously (25). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (MTT) was purchased from Molecular Probes Inc.
(Eugene, OR, USA). Propidium iodide (PI) and acridine orange (AO)
was purchased from SigmaeAldrich Co. (St. Louis, MO, USA). Phe-
nylmethylsulfonyl ﬂuoride (PMSF) was purchased from BD Bio-
sciences (San Jose, CA, USA). Annexin V-ﬂuorescein isothiocyanate
(FITC) was purchased from Merk Millipore (Billerica, MA, USA).
RPMI 1640, Dulbecco's modiﬁed Eagle's minimum essential me-
dium (DMEM), fetal bovine serum (FBS), penicillin, and strepto-
mycin were obtained from Life Technologies Inc. (Grand Island, NY,
USA). The primary antibodies for phospho-JNK, JNK, phospho-ERK,
beclin-1, p62, and b-actin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). LC3 I/II, phospho-p38, p38,
ERK, phospho-mTOR, and mTOR were obtained from Cell Signaling
(Beverly, MA, USA). Autophagy inhibitor baﬁlomycinA1 (BaF1), JNK
inhibitor SP600125, and p38 inhibitor SB203580 were purchased
from SigmaeAldrich Co. mTOR activator MHY-1485 was obtained
from Merk Millipore (Billerica, MA, USA).
2.2. Cell culture and MTT assay
Human ovarian cancer cell SKOV3, A2780 and OVCAR3 and
human endometrial cancer cell Hec1A are originally obtained from
American Type Culture Collection. Human endometrial cancer cell
Ishikawa was purchased from SigmaeAldrich Co. The cells were
cultured in RPMI 1640 or DMEM supplemented with 5% fetal
bovine serum (FBS), penicillin (100 U/mL) and streptomycin sul-
fate (100 mg/mL). The cytotoxicity was assessed by using the MTT
assay. Brieﬂy, the cells were seeded in each well containing 50 mL
of RPMI 1640 or DMEM medium in a 96-well plate. After 24 h,various concentrations of eclalbasaponin I, eclalbasaponin II,
ecninocystic acid or cisplatin (1.5625, 3.125, 6.25, 12.5, 25, 50, 100
or 200 mM) were added. After 48 h, 25 mL MTT (5 mg/mL stock
solution) was added, and the plates were incubated for an addi-
tional 3 h. The medium was discarded, and the formazan blue,
which was formed in the cells, was dissolved in 50 mL DMSO. The
optical density was measured at 540 nm using a microplate
spectrophotometer (SpectraMax; Molecular Devices, Sunnyvale,
CA, USA).2.3. Propidium iodide (PI) staining for cell cycle distribution
analysis
On the day of collection, the cells at density of 1  105 (SKOV3)
and 1.2  105 (A2780) were harvested and washed twice with ice-
cold PBS. The cells were ﬁxed and permeabilized with 70% ice-cold
ethanol at 4 C at least for 4 h. The cells werewashed oncewith PBS
and resuspended in a staining solution containing propidium io-
dide (50 mg/ml) and RNaseA (250 mg/ml). The cell suspensions were
incubated for 30 min at room temperature in the dark place. The
ﬂuorescence intensity of individual cells was measured by
ﬂuorescence-activated cell sorting (FACS) cater-plus ﬂow cytom-
etry (Becton Dickinson Co., Germany); at least 10,000 cells per each
group were counted.2.4. Annexin V-FITC staining assay for apoptosis analysis
During apoptosis, the exposure of phosphatidylserine on the
exterior surface of the plasma membrane can be detected by the
binding of ﬂuoresceinated annexin V (annexin V-FITC). This assay
is combined with analysis of the exclusion of the plasma mem-
brane integrity probe PI. To double stain annexin V and PI, the cells
were suspended with 100 mL of fresh media (No FBS RPMI 1640)
and stained with 100 mL of FITC-conjugated annexin V. The
mixture was incubated for 20 min at 4 C in a dark place and
analyzed using FACS cater-plus ﬂow cytometry (guava easy cyte™,
Merk Millipore, Germany); at least 10,000 cells per each group
were counted.2.5. Western blot analysis
Eclalbasaponin II-treated SKOV3 and A2780 cells were collected
by centrifugation (2500 rpm, 10 min, 4 C). The cells were then
washed twice with ice-cold PBS and centrifuged (1st; 2500 rpm,
10 min, 4 C and 2nd; 15,000 rpm, 5 min, 4 C). The cell pellet was
extracted in protein lysis buffer (Intron, South Korea). The protein
concentration was determined by the Bradford assay. The protein
samples of cell lysate were mixed with an equal volume of 5X SDS
sample buffer, boiled for 5 min, and then separated on 6e15%
SDSePAGE gels. After electrophoresis, proteins were transferred to
polyvinylidene diﬂuoride (PVDF) membranes. The membranes
were blocked in 2.5e5% non-fat dry milk for 30 mine1 h, washed,
and incubated with speciﬁc primary antibodies (LC3 I/II, b-actin,
phospho-JNK, total-JNK, phospho-p38, total-p38, phospho-ERK,
total-ERK phospho-mTOR and total-mTOR) in 2.5% or 5% non-fat
dry milk overnight at 4 C. Primary antibodies were removed by
washing the membranes three times in TBS-T (Tris-buffered saline
(TBS) containing Tween-20 (0.1%)), and then the membranes were
incubated for 3 h with horseradish peroxidase-conjugated sec-
ondary antibody (1:1000e2000). Following three washes in TBS-T,
immune-positive bands were visualized by enhanced chem-
iluminescence and exposed to Image Quant LAS-4000 (Fujiﬁlm Life
Science, Japan).
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Acidic intracellular compartments were visualized by acridine
orange staining. After SKOV3 and A2780 human ovarian cancer
cells were seeded at a density of 7 103 (SKOV3) or 8 103 (A2780)
per well into 4-well slide chamber, the cells were treated with
eclalbasaponin II and incubated for an additional 48 h. Then, the
cells were washed twice with phosphate-buffered saline (PBS) and
ﬁxed with 4% formaldehyde for 10 min. After ﬁxing, Following
washes in PBS, cells were stained with acridine orange (10 mg/ml)
for 15 min at 37 C temperature in the dark. Subsequently, the cells
were washed by PBS and observed under a CKX41 ﬂuorescence
microscope (Olympus, Tokyo, Japan).2.7. Statistical analysis
Data are presented as the mean ± SD of three individual ex-
periments performed in triplicate. Student's t-test and one-way
ANOVA were used to identify statistically signiﬁcant differences.
P-values < 0.05 were considered to be statistically signiﬁcant.3. Results
3.1. Growth inhibitory effect of echinocystic acid and its glycosides
isolated from E. prostrata in human ovarian and endometrial cancer
cells
To investigate the cytotoxicity of triterpenoid echinocystic acid
and its glycoside eclalbasaponin I and eclalbasaponin II, we evalu-
ated the IC50 using MTT assay in human ovarian cancer cells
(SKOV3, OVACAR3, and A2780) and endometrial cancer cells
(HEC1A and ISHIKAWA). As shown in Table 1, aglycone echinocystic
acid and its glycoside eclalbasaponin II (a glucose moiety at C-3
position) showed relatively good cytotoxicity in all ﬁve gyneco-
logical cancer cells. In contrast, eclalbasaponin I with glucose
moieties at C-3 and C-28 positions, showed a mild growth inhibi-
tory effect only in A2780 (IC50 ¼ 94.87 mM), but not in other types
of cells (IC50 > 200 mM). Interestingly, the IC50 values of eclalba-
saponin II with a glucose moiety at C-3 position were smaller than
that of its aglycone in all ﬁve cancer cells. Thus, we further inves-
tigated themolecular mechanism underlying the growth inhibitory
effect of eclalbasaponin II in ovarian cancer cells.Table 1
Cytotoxic activity of compounds isolated from Eclipta prostrata L. in human gynecologica
Compound Cytotoxicity IC50a (mM)
Human ovarian cancer cells
SKOV3 A2780
Echinocystic acid 43.04 ± 3.68 38.64 ± 0.30
Eclalbasaponin I >200 94.87 ± 6.37
Eclalbasaponin II 20.39 ± 1.19 22.12 ± 3.90
a IC50 is deﬁned as the concentration that results in a 50% decreased in the number of
three independent experiments with similar patterns.3.2. Eclalbasaponin II induces apoptosis in SKOV3 and A2780
ovarian cancer cells
To determine whether the growth inhibitory effect was associ-
ated with the induction of cell cycle arrest and/or apoptosis, the
distribution of cells in each phases of the cell cycle was analyzed
using ﬂow cytometry. As shown in Fig. 1A and B, eclalbasaponin II
treatment induced an increase in sub G1 phase in SKOV3 and A2780
in a dose dependent manner. For example, treatment with 10, 20
and 30 mM eclalbasaponin II increased the percentage of cells in the
sub G1 phase up to 11.7, 17.9 and 42.0%, respectively, in A2780 cells.
No signiﬁcant cell cycle arrest following eclalbasaponin II treat-
ment was observed in either SKOV3 or A2780 cells. To conﬁrm the
eclalbasaponin II-induced apoptosis, an annexin V-FITC staining
assay was performed with both SKOV3 and A2780 cells. Treatment
with eclalbasaponin II signiﬁcantly increased the populations of
annexin Vepositive cells (apoptotic cells) in the right quadrants of
ﬂow cytometry graphs in a dose dependent manner (Fig. 2A and B).
These results indicate that the eclalbasaponin II-induced growth
inhibitory effect is mediated by induction of apoptosis rather than
cell cycle arrest in human ovarian cancer cells. Apoptosis, type I
programed cell death, is a cell-suicide mechanism, in which the
caspase family of cysteine protease plays a critical role. However,
we failed to observe any signiﬁcant change in the activation of the
caspases such as caspase-3 and caspase-9 following eclalbasaponin
II treatment in SKOV3 and A2780 (data not shown). These data
suggest that eclalbasaponin II may induce apoptosis in a caspase-
independent manner in ovarian cancer cells.3.3. Eclalbasaponin II induces autophagy in SKOV3 and A2780
ovarian cancer cells
We next determined whether eclalbasaponin II affected the
autophagy pathway. Acridine orange staining was performed to
analyze the formation of acidic vesicular organelles (AVO), a main
feature of autophagy. As shown in Fig. 3A and B, eclalbasaponin II
induced evident formation of grange AVOs in SKOV3 and
A2780 cells. Control cells treated with vehicle (DMSO) displayed
green ﬂuorescence, indicating the lack of AVOs. In addition, we
performed Western blot analysis to measure the levels of
microtubule-associated protein 1 light chain 3 (LC3)-II, a prom-
ising autophagosomal marker. Treatment with eclalbasaponin II
markedly increased the LC3-II levels in a time-dependent mannerl cancer cells.
Human endometrial cancer cells
OVCAR3 HEC1A Ishikawa
99.14 ± 2.84 39.73 ± 6.69 134.60 ± 10.67
>200 >200 >200
40.80 ± 0.65 39.43 ± 1.41 82.57 ± 8.70
cells compared to that of the control. The values represent the means of results from
Fig. 1. Effect of eclalbasaponin II isolated from Eclipta prostrata L. on cell cycle distribution in SKOV3 (A) and A2780 (B) human ovarian cancer cells. The cell cycle distribution proﬁle
of SKOV3 and A2780 human ovarian cancer cells were determined by ﬂow cytometry analysis (FACS). (A) SKOV3 cells were treated with 10, 12.5, 25 mM of eclalbasaponin II for 48 h.
(B) A2780 cells were treated with 10, 20, 30 mM of eclalbasaponin II for 48 h. After treatment with eclalbasaponin II for 48 h, SKOV3 and A2780 cells were stained with propidium
iodide (PI). The graphs show the distribution of cells in the cell cycle. Representative histograms indicate the percentage of cells in the sub G1, G0/G1, S and G2/M phase of cell cycle.
The percentage of cells with sub G1 DNA content was taken as a measure of the apoptotic cell population. The data are representative of three different experiments.
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SKOV3 and A2780 cells. An increase in autophagy is generally
accompanied by an increase in beclin-1 protein and decrease in
p62 protein. We found that eclalbasaponin II increased beclin-
1and decreased p62 in both SKOV3 (Fig. 3G) and A2780 cells
(Fig. 3H).Fig. 2. Effect of eclalbasaponin II isolated from Eclipta prostrata L. on apoptotic cell death ind
was determined by ﬂow cytometry analysis (FACS). SKOV3 (A) and A2780 (B) were treated wi
and 48 h), and then were co-stained with PI and FITC-conjugated annexin V. The transloca3.4. Autophagy is associated with eclalbasaponin II-induced
apoptotic cell death in SKOV3 and A2780 ovarian cancer cells
To elucidate the role of autophagy in eclalbasaponin II-induced
apoptotic cell death, autophagy inhibitor baﬁlomycin A1 (BaF1) was
used. As shown in Fig. 4A and B, treatment with eclalbasaponin IIuction in SKOV3 (A) and A2780 (B) human ovarian cancer cells. The apoptotic cell death
th eclalbasaponin II (SKOV3; 25 mM, A2780; 30 mM) for the indicated times (0, 12, 24, 36
tion of phosphatidylserine was detected by ﬂow cytometry.
Fig. 3. Ecalabasaponin II induces autophagy in SKOV3 (A, C, E and G) and A2780 (B, D, F and H) human ovarian cancer cells. (A and B) SKOV3 and A2780 cells were treated with
25 mM, and 30 mM of eclalbasaponin II, respectively, for 48 h. The acridine orange staining was performed to conﬁrm the formation of acidic vacuoles inside the cytoplasm. Scale
bars, 10 uM. (C and D) SKOV3 and A2780 cells were treated with eclalbasaponin II (SKOV3; 25 mM, A2780; 30 mM) for the indicated times (0, 12, 24, 36 and 48 h). Western blot assays
were performed to measure the protein levels of LC3 I/II and b-actin. (EeH) SKOV3 cells (E and G) were treated with 10, 12.5, 25 mM of eclalbasaponin II for 48 h. A2780 cells (F and
H) were treated with 10, 20, 30 mM of eclalbasaponin II for 48 h. Western blot assays were performed to measure the protein levels of beclin-1, p62, and b-actin.
Fig. 4. Eclalbasaponin II-induced autophagic cell death was inhibited by BaF1, common autophagy inhibitor, in SKOV3 (A) and A2780 (B) human ovarian cancer cells. SKOV3 (A) and
A2780 (B) cells were pretreated with and without the autophagy inhibitor BaF1 (1 nM or 2 nM) for 30 min, and then eclalbasaponin II (SKOV3; 25 mM, A2780; 30 mM) was added for
48 h. MTT assay was performed to determine the change of eclalbasaponin II-induced cell death. The value are expressed as means ± SD of three individual experiments (#P < 0.05
as compared with the control group and *P < 0.05 as compared with the eclalbasaponin II-only treated group).
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Fig. 6. Eclalbasaponin II-induced autophagic and apoptotic cell death is associated
with mTOR, p38, and JNK signaling in A2780 human ovarian cancer cells. A2780 cells
were treated with eclalbasaponin II (30 mM) for the indicated times (0, 15, 30, 60, and
120 min). Phospho- and pan-p38, JNK, ERK, and mTOR were analyzed by Western blot
assay with the speciﬁc antibodies. b-actin was used as the loading control. The data are
representative of three different experiments.
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the suppressionwas signiﬁcantly attenuated by BaF1 pretreatment.
In addition, an annexin V-FITC staining assay revealed that eclal-
basaponin II-induced apoptosis is signiﬁcantly reduced by BaF1 in
A2780 cells (Fig. 5). These data suggested that eclalbasaponin II-
induced apoptosis is mediated by autophagy in human ovarian
cancer cells.
3.5. Eclalbasaponin II-induced autophagy and apoptosis are
associated with JNK, p38, and mTOR signaling in ovarian cancer
cells
We next investigated the effect of eclalbasaponin II on MAPK
and mTOR signaling pathways, which have been suggested to
regulate apoptosis and/or autophagy. Western blot analysis were
performed to elucidate the protein levels and phosphorylation of
p38, JNK, ERK, and mTOR after the treatment of A2780 cells with
eclalbasaponin II (30 mM). As shown in Fig. 6, eclalbasaponin II
increased phosphorylation of p38 and JNK, whereas the phos-
phorylation of mTOR decreased in a time-dependent manner (0, 15,
30, 60, and 120 min). In contrast, no signiﬁcant change in phos-
phorylation of ERK was observed. To further conﬁrm the involve-
ment of JNK, p38, and mTOR signaling in the eclalbasaponin II-
induced cell death, p38 inhibitor SB203580, JNK inhibitor
SP600125, and mTOR activator MHY1485 were used at concentra-
tions that signiﬁcantly modulated the activation of their corre-
sponding proteins. SB203580, SP600125, and MHY1485 partially
but signiﬁcantly reversed the eclalbasaponin II-induced cell growth
inhibition (Fig. 7A and C and Supple. Fig. 1) and LC3-II accumulation
(Fig. 7B and D) in A2780 cells. These results indicated that the
eclalbasaponin II-induced apoptosis is mediated by autophagy via
JNK, p38, and mTOR signaling in ovarian cancer cells.
4. Discussion
E. prostrata, a member of perennial herb of the family Aster-
aceae, is a widely distributed medicinal plant. E. prostrata is used in
Asian traditional medicine to treat infectious hepatitis, jaundice,
liver cirrhosis, aching and weakness of the knees and joints, he-
maturia, diarrhea with bloody stools, and abnormal uterine
bleeding (15). This plant has been reported to possess wide range of
biological activities including hepatoprotective activity (26,27),
immunomodulatory (28), anti-oxidant (17), anti-microbial (29),
anti-inﬂammatory (15,30), hypolipidemic (31), analgesic (32), anti-Fig. 5. The pretreatment with autophagy inhibitor BaF1 decreased eclalbasaponin II-
induced apoptotic cell death in A2780 human ovarian cancer cells. Effect of auto-
phagy inhibitor BaF1 on eclalbasaponin II-induced apoptotic cell death in A2780 hu-
man ovarian cancer cells was detected by ﬂow cytometry (FACS). A2780 cells were
pretreated with and without the autophagy inhibitor BaF1 (1 nM) for 30 min, and then
eclalbasaponin II (30 mM) was added for 48 h. Cells were co-stained with FITC-
conjugated annexin V. The translocation of phosphatidylserine was detected by ﬂow
cytometry after eclalbasaponin II treatment. The data are representative of three in-
dividual experiments (#P < 0.05 as compared with the control group and *P < 0.05 as
compared with the eclalbasaponin II-only treated group).venom (33), and anti-aging (34). However, many studies on the
biological activities of the plant were conducted using crude ex-
tracts. In fact, although anti-cancer activities of E. prostrate has been
suggested (16,22,23), the tumoricidal activity of compounds iso-
lated from E. prostrata in human cancer cells and their molecular
mechanism of action have been poorly understood. Here, we
investigated the cytotoxicity of three oleanane-type pentacyclic
triterpenoids isolated from E. prostrate in human ovarian and
endometrial cancer cells. The three triterpenoids only differ in the
substitution in C-3 and C-28 position; an aglycone echinocystic acid
and its glycoside eclalbasaponin II (a glucose moiety at C-3 posi-
tion) and eclalbasaponin I (a glucose moiety each at C-3 and C-28
position). We have demonstrated that the cytotoxic activity of the
compounds in both ovarian and endometrial cancer cells was in the
following order: eclalbasaponin II > echinocystic
acid [ eclalbasaponin I. These data suggest that the cytotoxic
activity of oleanane-type triterpenoids having echinocystic acid
skeleton as an aglycone is associated with the existence of a free
carboxylic group at C-28 position and the presence of the sugar
moiety at the C-3 position. This ﬁnding is consistent with previous
ﬁndings that the existence of a free carboxyl at C-28 in oleanane-
type triterpenoids is important for anti-tumor activity (35). In
addition, structure-activity studies for triterpenoid saponins have
suggested that the cytotoxic activity of the saponins signiﬁcantly
Fig. 7. Eclalbasaponin II-induced autophagic cell death is associated with mTOR, p38,
and JNK signaling in A2780 human ovarian cancer cells. (A and C) A2780 cells were
pretreated with or without SB203580 p38 inhibitor (20 mM), SP600125 JNK inhibitor
(10 mM), or MHY-1485 mTOR activator (1 or 2 mM) for 30 min, and then eclalbasaponin
II (30 mM) was added for 48 h. Cell viabilities were determined using an MTT assay. The
value are expressed as means ± SD of three individual experiments (#P < 0.05 as
compared with the control group and *P < 0.05 as compared with the eclalbasaponin
II-only treated group). (B and D) A2780 cells were pretreated with or without
SB203580 p38 inhibitor (20 mM), SP600125 JNK inhibitor (10 mM), MHY-1485 mTOR
activator (2 mM) for 30 min, and then eclalbasaponin II (30 mM) was added for 24 h.
Western blot analysis was performed to measure the expression level of LC3 I/II. b-
actin was used as a loading control. The data are representative of three different
experiments.
Y.J. Cho et al. / Journal of Pharmacological Sciences 132 (2016) 6e1412varied according to the nature of the sugar moieties linked to C-3
(36). It is of note that, among the three compounds, eclalbasaponin
II also showed the most potent cytotoxic activity against breast and
liver cancer cells (Supple. Table 1).
In the present study, we found that eclalbasaponin II induces
apoptosis in a caspase-independent manner in human ovarian
cancer cells. We further investigated whether eclalbasaponin II
induced autophagic cell death; type II programmed cell death,
which is not dependent on the activation of caspases. Autophagy, a
cellular self-degradation operation, can function in cyto-protectionby reducing cellular metabolic stress or in promoting cell death,
depending on the cell type and different stresses. The role of
autophagy in cancer is also paradoxical as it has dual roles in cell
survival and death (37). LC3 is important proteins in autophagy,
during which cytoplasmic pattern LC3 (LC3-I) is converted to
autophagosomal membrane LC3 (LC3-II), leading to increased LC3-
II levels (38). Beclin-1, the mammalian orthologue of yeast Atg6,
play a critical role in the formation autophagosome (39). Auto-
phagic cargo receptors containing an LC3-interacting region (LIR)
such as p62 directly binds to LC3 (40). p62-positive bodies are
degraded within the autolysosomes. It is of interest that many anti-
cancer natural substances have been reported to induce autophagy
in various cancer cells (41e43). We found that eclalbasaponin II
increased the expression of LC3-II in a time and dose-dependent
manner. In addition, growth inhibitory effect of eclalbasaponin II
was effectively reversed by pre-treatment with an autophagy in-
hibitor BaF1 in ovarian cancer cells. Furthermore, annexin V
staining assay also revealed that BaF1 signiﬁcantly reduced eclal-
basaponin II-induced apoptosis. These results suggested that
eclalbasaponin II-induced autophagy may play a key role in
apoptotic cell death in human ovarian cancer cells.
Autophagy is a complex and multi-step procedure that is
suggested to involve many signaling molecules including mTOR
and MAPK pathway. mTOR signaling is a key regulator of physi-
ological cell processes including proliferation, differentiation,
apoptosis, motility, metabolism, and autophagy (44,45). The
mTOR, a key negative regulator of autophagy, is known to lie
upstream of many autophagy-associated genes (46,47). Rapamy-
cin, a speciﬁc inhibitor of mTOR pathway signaling, can induce
autophagy in several human cancer cells including lung cancer,
glioma, lymphoma, and gastric cancer (48e50). Here, we found
that eclalbasaponin II markedly inhibited the mTOR activation,
and the eclalbasaponin II-induced cell death and LC3-II accumu-
lation were signiﬁcantly reversed by mTOR activator MHY-1485 in
human ovarian cancer cells. The present ﬁnding is consistent with
previous reports that suppression of the mTOR signaling may
contribute to the autophagic cell death (43,51e53). In contrast to
suppression of mTOR signaling by eclalbasaponin II, MAP kinase
JNK and p38 were found to be activated by eclalbasaponin II in
A2780 cells. No signiﬁcant change in ERK signaling was observed.
In fact, involvement of JNK and p38 signaling in autophagic cell
death has been suggested (54e56). For example, pieprlongumine,
an alkaloid isolated from Piper Longum, induced autophagic cell
death by stimulating p38 signaling (57). Puissant et al. demon-
strated that resveratrol promotes autophagic cell death in leuke-
mia cells via the JNK pathway (58). It is of note that the mTOR
pathway in autophagy has been suggested to be regulated by the
MAPK pathway (59,60). Whether JNK and p38 activation by
eclalbasaponin II acts upstream or downstream of the mTOR in-
hibition remain to be elucidated.
In conclusion, our study provide the ﬁrst evidence that eclal-
basaponin II induces autophagic and apoptotic cell death by regu-
lating mTOR and MAP kinase JNK and p38 in human ovarian cancer
cells. The ﬁndings reported herein provide a molecular basis for the
effects underlying the use of E. prostrate (False Daisy) and eclalba-
saponin II as potential therapeutic agents for ovarian cancer.
However, the detailed mechanism underlying eclalbasaponin II-
induced autophagy, such as the upstream signaling of JNK and p38
of MAPK pathway, will require further exploration. In order to
completely investigate eclalbasaponin II-induced autophagy,
additional in vivo studies are also required. Importantly, however,
the ﬁndings of these results make eclalbasaponin II an attractive
therapeutic agent for promising approach for exploring the po-
tential anti-cancer role of eclalbasaponin II and possibly, for
developing alternative treatment.
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